Table 8.
Breakthrough reactions in patients undergoing platin desensitization
| Study | Agent | No. of steps in desensitization | No. of desensitizations completed | No. of patients with BTR | Severe BTR, n (% desensitizations) | No. of patients unable to complete treatment due to BTR |
|---|---|---|---|---|---|---|
| Lee et al. (2004) [51] | Carboplatin | 12 | 35 | 4/10 (40%) | 0 | 0 |
| Lee et al. (2005) [53] | Carboplatin | 12 | 127 | 11/31 (35%) | 1 (0.8%) | 0 |
| Hesterberg et al. (2009) [4] | Carboplatin | 8 or 10 | 105 | 13/30 (43%) | 1 (0.9%) | 1 |
| Patil et al. (2012) [36] | Carboplatin | 8 or 12 | 148 | 23/39 (59%) | 0 | 0 |
| Wong et al. (2014) [14] | Oxaliplatin | 8 or 13 | 200 | 17/48 (35%) | 1 (0.5%) | 0 |
| Sloane et. al. (2016) [31] |
Carboplatin Cisplatin Oxaliplatin |
12–16a | Carboplatin 1069 | NR; 253 (24%) carboplatin desensitizations had mild HSR and 87 (8%) had moderate–severe HSR | Carboplatin 41 (4%) | 0 |
| Mawhirt et al. (2018) [54] |
Carboplatin Oxaliplatin |
12 | 146b | 21/36 (58%)b | 3 (2%)b | NR |
BTR breakthrough reaction, NR not reported
aA total of 22 desensitizations were performed that were < 12 steps
bData is combined for carboplatin and oxaliplatin as results of desensitizations were not distinguished